

People

A sample of goings-on in and around the biotech and pharmaceutical industry.



Cancer detection start-up Grail has announced the appointment of **Hans Bishop** (photo) as CEO. He succeeds **Jennifer Cook**, who stepped down as CEO and a member of the board of directors for family health reasons. Bishop has served on Grail's board since August 2018 and will continue to serve as a director. He has over 30 years of experience in the biotech industry and currently serves as the executive chair of the Sana board of directors and as a director of Celgene, Agilent Technologies and Lyell Immunopharma. Previously, Bishop founded Juno Therapeutics and served as its president and CEO until its acquisition by Celgene in March 2018.

In addition, Grail has announced the appointment of **Joshua Ofman**, most recently Amgen's senior vice president of global health policy, as chief of corporate strategy and external affairs, and **Maykin Ho**, a partner at Qiming Venture Partners, as an independent director on Grail's board.



Nkechi Azie (photo) has been appointed vice president of clinical development at Scynexis. She will lead clinical

development activities and strengthen medical affairs efforts in anticipation of the potential approval and commercial launch of the company's first-in-class antifungal, ibrexafungerp. Most recently, Azie served as senior vice president of medical affairs at The Medicines Company.

The board of directors of Sanofi has unanimously appointed **Paul Hudson** to succeed the retiring **Olivier Brandicourt** as CEO, effective 1 September. Hudson is a seasoned leader with a strong international experience, particularly in the United States, Japan and Europe. He has spent his 28-year career with major pharma companies such as Schering Plough, Astra Zeneca and most recently Novartis, where he was CEO.

Jazz Pharmaceuticals has announced the appointment of **Robert Iannone** as executive vice president, R&D. Iannone joins Jazz from Immunomedics, where he served as chief medical officer and head of R&D.

Clinical-stage biopharma F-star has named **Louis Kayitalire** as chief medical officer. Kayitalire bring over 20 years' experience in oncology and immuno-oncology, having

previously held positions at Bristol-Myers Squibb, Celgene and Eli Lilly.

Domain Therapeutics has announced the appointment of **Xavier Leroy** as chief technology officer. Leroy spent 13 years at Actelion Pharmaceuticals in positions of increasing seniority. Most recently he was head of drug discovery at Belgium-based iTeos. Domain also named **Sylvie Ryckebusch** to its board of directors. Ryckebusch previously served as head of licensing in neurology and autoimmune disease at Merck Serono and was most recently chief business officer at the EspeRare Foundation.

Oslo-based Zelluna Immunotherapy has named **Jens-Peter Marschner** as chief medical officer. Marschner is a medical doctor who brings more than 20 years experience in clinical development and medical affairs. Before joining Zelluna, he served as medical lead oncology for Western Europe and Canada at AbbVie and as CMO for Affimed.

Molecular Devices has announced the appointment of **Susan Murphy** as president, succeeding **Greg Milosevich**, who has been appointed president of Beckman Coulter Life Sciences, which is owned by Molecular Devices' parent company, Danaher. Murphy has held various positions of increasing responsibilities at Molecular Devices, most recently vice president & general manager of commercial operations in western markets,

where she led sales and all aspects of global marketing.

Spanish biopharma Sanifit has announced the appointments of **Guy Paul Nohra** of Alta Life Sciences and **Damià Tormo** of Columbus Venture Partners as non-executive members of the board of directors, in conjunction with the completion of an \$81 million private financing round.

Autoimmunity biopharma Immunovant has named **Pete Salzmann** as CEO. Salzmann brings 20 years of experience from various leadership roles at Eli Lilly, most recently as global clinical development leader for Olumiant (baricitinib).

Jeff Settleman has joined Pfizer as senior vice president and group head of oncology R&D, leading all early oncology research, from discovery to proof-of-concept clinical studies. He joins the company from Calico Life Sciences, where he was distinguished principal investigator and head of oncology research. Before Calico, Settleman led discovery oncology at Genentech. In addition, Pfizer announced the election of **Scott Gottlieb** to its board of directors, effective immediately. Gottlieb resigned as commissioner of the US Food and Drug Administration in March. In May, he was named special partner at venture firm New Enterprise Associates.

Christopher Tompkins has been named CEO of KromaTiD. Tompkins joined the company in 2010 and has previously served as president, general manager and chief technology officer.

Harald zur Hausen, recipient of the 2008 Nobel Prize in Medicine for the discovery that viruses cause some types of cancer, has been named to lead the European Union's research mission on cancer under Horizon Europe. Zur Hausen and four other mission board chairs will now set out targets and timelines for each research mission, with proposals due to be submitted by the end of the year. □

Published online: 2 August 2019
<https://doi.org/10.1038/s41587-019-0218-8>